NO20054169L - 3-(1-[3-(1,3-benzotiazol-6-yl) propylkarbamoyl]sykloalkyl]propansyrederivater som NEP-inhibitorer. - Google Patents

3-(1-[3-(1,3-benzotiazol-6-yl) propylkarbamoyl]sykloalkyl]propansyrederivater som NEP-inhibitorer.

Info

Publication number: NO20054169L
Authority: NO; Norway
Prior art keywords: propylcarbamoyl; benzothiazol; cycloalkyl; inhibitors; acid derivatives
Prior art date: 2003-03-14

Application number

NO20054169A

Other languages

English (en)

Norwegian (no)

Other versions

NO20054169D0 (no

Inventor

David Hepworth

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-03-14

Filing date

2005-09-07

Publication date

2005-12-07

2003-03-14 Priority claimed from GB0305916A external-priority patent/GB0305916D0/en

2003-12-16 Priority claimed from GB0329143A external-priority patent/GB0329143D0/en

2005-09-07 Application filed by Pfizer filed Critical Pfizer

2005-09-07 Publication of NO20054169D0 publication Critical patent/NO20054169D0/no

2005-12-07 Publication of NO20054169L publication Critical patent/NO20054169L/no

Links

239000003112 inhibitor Substances 0.000 title abstract 4
-1 1,3-benzothiazol-6-yl Chemical group 0.000 title 1
XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 title 1
125000000753 cycloalkyl group Chemical group 0.000 title 1
206010057671 Female sexual dysfunction Diseases 0.000 abstract 4
208000021663 Female sexual arousal disease Diseases 0.000 abstract 2
102000003729 Neprilysin Human genes 0.000 abstract 2
108090000028 Neprilysin Proteins 0.000 abstract 2
206010057672 Male sexual dysfunction Diseases 0.000 abstract 1
239000000543 intermediate Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Hematology (AREA)
Cardiology (AREA)
Psychiatry (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Addiction (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Reproductive Health (AREA)
Ophthalmology & Optometry (AREA)
Dermatology (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)
Gynecology & Obstetrics (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Pregnancy & Childbirth (AREA)
Vascular Medicine (AREA)
Gastroenterology & Hepatology (AREA)

NO20054169A 2003-03-14 2005-09-07 3-(1-[3-(1,3-benzotiazol-6-yl) propylkarbamoyl]sykloalkyl]propansyrederivater som NEP-inhibitorer. NO20054169L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0305916A GB0305916D0 (en)	2003-03-14	2003-03-14	New N-phenpropylcyclopentyl-substituted glutaramide derivatives as NEP inhibitors
GB0329143A GB0329143D0 (en)	2003-12-16	2003-12-16	Novel pharmaceuticals
PCT/IB2004/000822 WO2004080985A1 (fr)	2003-03-14	2004-03-09	Derives d'acide 3-(1-[3-(1,3-benzothiazol-6-yl)propylcarbamoyl]cycloalkyl)propanoique agissant comme inhibiteurs de la nep

Publications (2)

Publication Number	Publication Date
NO20054169D0 NO20054169D0 (no)	2005-09-07
NO20054169L true NO20054169L (no)	2005-12-07

Family

ID=32992599

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20054169A NO20054169L (no)	2003-03-14	2005-09-07	3-(1-[3-(1,3-benzotiazol-6-yl) propylkarbamoyl]sykloalkyl]propansyrederivater som NEP-inhibitorer.

Country Status (25)

Country	Link
US (1)	US20040180941A1 (fr)
EP (1)	EP1606272A1 (fr)
JP (1)	JP3923512B2 (fr)
KR (1)	KR20050110003A (fr)
AP (1)	AP2005003393A0 (fr)
AR (1)	AR043551A1 (fr)
AU (1)	AU2004220269A1 (fr)
BR (1)	BRPI0408377A (fr)
CA (1)	CA2519072A1 (fr)
CL (1)	CL2004000512A1 (fr)
EA (1)	EA200501204A1 (fr)
EC (1)	ECSP056017A (fr)
HR (1)	HRP20050797A2 (fr)
IS (1)	IS8003A (fr)
MA (1)	MA27720A1 (fr)
MX (1)	MXPA05009788A (fr)
NL (1)	NL1025709C2 (fr)
NO (1)	NO20054169L (fr)
OA (1)	OA13039A (fr)
PA (1)	PA8597401A1 (fr)
PE (1)	PE20050310A1 (fr)
TN (1)	TNSN05227A1 (fr)
TW (1)	TW200504038A (fr)
UY (1)	UY28226A1 (fr)
WO (1)	WO2004080985A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2575706A1 (fr) *	2004-08-02	2006-02-23	Bebaas, Inc.	Compositions de vitamine b<sb>12</sb>
WO2006027680A1 (fr) *	2004-09-10	2006-03-16	Pfizer Limited	Derives d'acide 3-(1-carbamoylcyclohexyl)propionique comme inhibiteurs de l'enzyme endopeptidase neutre
WO2006066361A1 (fr) *	2004-12-24	2006-06-29	The University Of Queensland	Procede de traitement ou prophylaxie
JP2009502961A (ja)	2005-07-29	2009-01-29	コンサートファーマシューティカルズインコーポレイテッド	新規な医薬組成物
US20070178141A1 (en) *	2005-09-07	2007-08-02	Bebaas, Inc.	Vitamin B12 compositions
US20130131007A1 (en)	2005-09-07	2013-05-23	Bebaas, Inc.	Vitamin b12 compositions
AU2007229322B2 (en) *	2006-03-20	2012-04-05	Novartis Ag	Method of treatment or prophylaxis inflammatory pain
WO2008021666A2 (fr) *	2006-08-18	2008-02-21	Morton Grove Pharmaceuticals, Inc.	Compositions stables de lévétiracétam et procédés
KR101177866B1 (ko)	2011-03-24	2012-08-28	주식회사 케이엠더블유	케이블 접속 장치
WO2019241588A1 (fr) *	2018-06-14	2019-12-19	Astrazeneca Uk Limited	Méthodes de traitement d'une dysfonction érectile avec une composition pharmaceutique d'inhibiteur de phosphodiestérase 5 spécifique de cgmp
WO2019241585A1 (fr) *	2018-06-14	2019-12-19	Astrazeneca Uk Limited	Méthodes de traitement d'une dysfonction érectile avec une composition pharmaceutique d'inhibiteur de phosphodiestérase 5 spécifique de cgmp
SG11202102791SA (en)	2018-09-25	2021-04-29	Antabio Sas	Indane derivatives for use in the treatment of bacterial infection
IL292775A (en) *	2019-11-08	2022-07-01	Vella Bioscience Inc	preparations containing cannabidiol (cbd) that act peripherally and their use to improve female sexual function or to treat female sexual disorders
GB202402524D0 (en) *	2024-02-22	2024-04-10	Futura Medical Developments Ltd	Topical composition

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2503059A (en) *		1950-04-04		Nxchj
US2599000A (en) *	1950-09-02	1952-06-03	Smith Kline French Lab	Nu, nu-disubstituted-beta-halo-alkylamines
US3238215A (en) *	1963-10-17	1966-03-01	Sterling Drug Inc	1-[(3-, 2-, and 1-indolyl)-lower-alkyl-, lower-alkenyl-, and lower-alkynyl]piperidines
IT1066857B (it) *	1965-12-15	1985-03-12	Acraf	Derivati della s ipiazolo 4.3 a piridina e processi per la loro preparazione
US3511836A (en) *	1967-12-13	1970-05-12	Pfizer & Co C	2,4,6,7-tetra substituted quinazolines
NL175059C (nl) *	1974-02-23		Boehringer Mannheim Gmbh	Bereiding van bloeddrukverlagende stoffen en van preparaten die ze bevatten.
US4026894A (en) *	1975-10-14	1977-05-31	Abbott Laboratories	Antihypertensive agents
US4188390A (en) *	1977-11-05	1980-02-12	Pfizer Inc.	Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
FR2421888A1 (fr) *	1978-02-06	1979-11-02	Synthelabo	Amides d'alkylene-diamines et leur application en therapeutique
IT1094076B (it) *	1978-04-18	1985-07-26	Acraf	Cicloalchiltriazoli
JPS56110665A (en) *	1980-02-08	1981-09-01	Yamanouchi Pharmaceut Co Ltd	Sulfamoyl-substituted phenetylamine derivative and its preparation
DE3528032A1 (de) *	1985-08-05	1987-02-05	Hoechst Ag	Verfahren zur herstellung 2-substituierter benzthiazole
PT100905A (pt) *	1991-09-30	1994-02-28	Eisai Co Ltd	Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
WO1996026940A1 (fr) *	1995-03-01	1996-09-06	Kyowa Hakko Kogyo Co., Ltd.	Derives d'imidazoquinazoline
GB9518953D0 (en) *	1995-09-15	1995-11-15	Pfizer Ltd	Pharmaceutical formulations
US6037346A (en) *	1997-10-28	2000-03-14	Vivus, Inc.	Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
EA006154B1 (ru) *	2001-03-28	2005-10-27	Пфайзер Инк.	N-фенпропилциклопентил-замещенные производные глутарамида в качестве nep ингибиторов при fsad

2004
- 2004-03-08 PA PA20048597401A patent/PA8597401A1/es unknown
- 2004-03-09 BR BRPI0408377-6A patent/BRPI0408377A/pt not_active IP Right Cessation
- 2004-03-09 WO PCT/IB2004/000822 patent/WO2004080985A1/fr not_active Ceased
- 2004-03-09 EA EA200501204A patent/EA200501204A1/ru unknown
- 2004-03-09 CA CA002519072A patent/CA2519072A1/fr not_active Abandoned
- 2004-03-09 OA OA1200500261A patent/OA13039A/en unknown
- 2004-03-09 AU AU2004220269A patent/AU2004220269A1/en not_active Abandoned
- 2004-03-09 HR HR20050797A patent/HRP20050797A2/hr not_active Application Discontinuation
- 2004-03-09 MX MXPA05009788A patent/MXPA05009788A/es unknown
- 2004-03-09 JP JP2006500337A patent/JP3923512B2/ja not_active Expired - Fee Related
- 2004-03-09 EP EP04718706A patent/EP1606272A1/fr not_active Withdrawn
- 2004-03-09 KR KR1020057017229A patent/KR20050110003A/ko not_active Ceased
- 2004-03-09 AP AP2005003393A patent/AP2005003393A0/xx unknown
- 2004-03-10 PE PE2004000259A patent/PE20050310A1/es not_active Application Discontinuation
- 2004-03-11 UY UY28226A patent/UY28226A1/es not_active Application Discontinuation
- 2004-03-11 AR ARP040100785A patent/AR043551A1/es unknown
- 2004-03-12 US US10/800,065 patent/US20040180941A1/en not_active Abandoned
- 2004-03-12 NL NL1025709A patent/NL1025709C2/nl not_active IP Right Cessation
- 2004-03-12 CL CL200400512A patent/CL2004000512A1/es unknown
- 2004-03-12 TW TW093106666A patent/TW200504038A/zh unknown
2005
- 2005-08-29 IS IS8003A patent/IS8003A/is unknown
- 2005-09-07 NO NO20054169A patent/NO20054169L/no not_active Application Discontinuation
- 2005-09-14 EC EC2005006017A patent/ECSP056017A/es unknown
- 2005-09-14 TN TNP2005000227A patent/TNSN05227A1/fr unknown
- 2005-09-14 MA MA28498A patent/MA27720A1/fr unknown

Also Published As

Publication number	Publication date
PE20050310A1 (es)	2005-05-04
AR043551A1 (es)	2005-08-03
HRP20050797A2 (en)	2006-02-28
IS8003A (is)	2005-08-29
AU2004220269A1 (en)	2004-09-23
OA13039A (en)	2006-11-10
PA8597401A1 (es)	2005-05-24
NL1025709A1 (nl)	2004-09-16
CL2004000512A1 (es)	2005-01-21
WO2004080985A1 (fr)	2004-09-23
MA27720A1 (fr)	2006-01-02
EA200501204A1 (ru)	2006-06-30
NL1025709C2 (nl)	2005-03-14
US20040180941A1 (en)	2004-09-16
TNSN05227A1 (fr)	2007-06-11
JP2006526572A (ja)	2006-11-24
EP1606272A1 (fr)	2005-12-21
MXPA05009788A (es)	2005-10-26
TW200504038A (en)	2005-02-01
JP3923512B2 (ja)	2007-06-06
BRPI0408377A (pt)	2006-03-21
NO20054169D0 (no)	2005-09-07
ECSP056017A (es)	2006-01-27
UY28226A1 (es)	2004-11-08
AP2005003393A0 (en)	2005-09-30
CA2519072A1 (fr)	2004-09-23
KR20050110003A (ko)	2005-11-22

Legal Events

Date	Code	Title	Description
2008-10-27	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20052796L (no)	2005-06-09	Indolylpyrazinonderivater anvendelige for behandling av hyper-proliferative forstyrrelser og sykdommer assosiert med angiogenese
NO20091560L (no)	2009-05-15	Biaryleterureaforbindelser
NO20053627L (no)	2005-08-10	Malonamidderivater som gamma-sekretase inhibitorer
NO20083411L (no)	2004-03-19	Indaneddiksyrederivater og deres anvendelse som farmasoytiske midler, intermediater og fremgangsmater for fremstilling
NO20051189L (no)	2005-05-10	1,3-diamino-2-hydroksypropan prodrogederivater
NO20082496L (no)	2008-07-24	Pyrazinderivater
NO20063761L (no)	2006-10-23	Sulfonamidderivater for behandling av sykdommer
TW200728305A (en)	2007-08-01	Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease
MXPA03011484A (es)	2004-03-18	Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
TW200512195A (en)	2005-04-01	Benzamide 2-hydroxy-3-diaminoalkanes
EA200700096A1 (ru)	2007-06-29	Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
MXPA05009788A (es)	2005-10-26	Derivados del acido 3-(1-[3- (1, 3-benzotiazol -6-il)propilcarbomil] cicloalquil) propanoico como inhibidores de endopeptidasa neutra.
ATE489951T1 (de)	2010-12-15	Thiazolidin-carbonsäureamid-derivate als modulatoren des prostaglandin-f-rezeptors
NO20056192L (no)	2005-12-27	Kapaseinhibitorer og anvendelse derav
CY1111327T1 (el)	2015-08-05	Υποκατεστημενα παραγωγα κυκλοεξυλοξεικου οξεος
NO20083708L (no)	2008-09-23	4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
SE0301368D0 (sv)	2003-05-09	Chemical compounds
ATE554766T1 (de)	2012-05-15	Amphiphile pyridinium-verbindungen, herstellungsverfahren und ihre verwendung
NO20064951L (no)	2006-10-30	1,3,4-oksadiazol-2-oner som PPAR delta-modulatorer og deres anvendelse
NO20060314L (no)	2006-04-06	Nicotinamid-derivater anvendbare som PDE4-inhibitorer
EP1817312A4 (fr)	2009-11-04	Inhibiteurs de l'aminopyridyle de la beta-secretase macrocyclique permettant de traiter la maladie d'alzheimer
EP2077719A4 (fr)	2010-12-08	Inhibiteurs pipéridines et pyrrolidines de la bêta-secrétase utilisés dans le traitement de la maladie d'alzheimer
NO20051011L (no)	2005-05-02	Kirale oksazol-arylpropionsyrederivater og anvendelse derav som PPAR agonister
NO20064982L (no)	2006-10-31	1,3,4-oksadiazol-2-oner som PPAR delta modulatorer og anvendelse derav
WO2006055434A3 (fr)	2007-07-05	Inhibiteurs de la beta-secretase formes d'amines tertiaires macrocycliques pour le traitement de la maladie d'alzheimer